PRIDOPIDINE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H23NO2S.ClH
Molecular Weight	317.875
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCCN1CCC(CC1)C2=CC=CC(=C2)S(C)(=O)=O

InChI

InChIKey=YGRHOYQMBLLGEV-UHFFFAOYSA-N

InChI=1S/C15H23NO2S.ClH/c1-3-9-16-10-7-13(8-11-16)14-5-4-6-15(12-14)19(2,17)18;/h4-6,12-13H,3,7-11H2,1-2H3;1H

HIDE SMILES / InChI

Description
Sources: https://web.stanford.edu/group/hopes/cgi-bin/hopes_test/pridopidine-huntexil-acr-16/
Curator's Comment: description was created based on several sources, including: http://adisinsight.springer.com/drugs/800017494 | https://en.wikipedia.org/wiki/Pridopidine

Pridopidine is an experimental drug candidate belonging to a class of agents known as dopidines, which act as dopaminergic stabilizers in the central nervous system. As a dopamine stabilizer, pridopidine is thought to reduce the effects of dopamine when there’s too much and increase its effects when there’s too little. Pridopidine, therefore, plays two opposing roles in the brain, which stabilize dopamine levels. In this way, pridopidine is thought to help the brain reestablish a normal balance of neurotransmitters, and thus regain control over motion. Pridopidine intended to treat Huntington’s disease movement symptoms. Pridopidine was well tolerated and had an adverse event profile similar to a placebo.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D2 receptor 297 Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19919834	Antagonist 2778		12.9 µM [IC50]
Sigma opioid receptor 63 Target ID: CHEMBL287 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26159455 \| http://www.tevapharm.com/news/teva_announces_results_from_exploratory_52_week_phase_2_pride_hd_study_of_pridopidine_in_huntington_disease_09_16.aspx	Agonist 2678		70.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Huntington's disease 24 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26881734 http://www.tevapharm.com/news/teva_announces_results_from_exploratory_52_week_phase_2_pride_hd_study_of_pridopidine_in_huntington_disease_09_16.aspx http://adisinsight.springer.com/drugs/800017494	Primary		Phase III 656	Unknown Approved Use Unknown
Schizophrenia 298 Sources: http://adisinsight.springer.com/drugs/800017494 https://www.ncbi.nlm.nih.gov/pubmed/14965231 https://www.ncbi.nlm.nih.gov/pubmed/15276693	Primary		Phase I 428	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
37.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26407011	45 mg 1 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TV-45065 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
804 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26407011	45 mg single, oral dose: 45 mg route of administration: Oral experiment type: SINGLE co-administered:	TV-45065 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
426 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26407011	45 mg 1 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PRIDOPIDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
263 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26407011	45 mg single, oral dose: 45 mg route of administration: Oral experiment type: SINGLE co-administered:	PRIDOPIDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
5141 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26407011	45 mg 1 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TV-45065 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
54.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26407011	45 mg single, oral dose: 45 mg route of administration: Oral experiment type: SINGLE co-administered:	TV-45065 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3851 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26407011	45 mg 1 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PRIDOPIDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2365 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26407011	45 mg single, oral dose: 45 mg route of administration: Oral experiment type: SINGLE co-administered:	PRIDOPIDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
13.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26407011	45 mg 1 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	TV-45065 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26407011	45 mg single, oral dose: 45 mg route of administration: Oral experiment type: SINGLE co-administered:	TV-45065 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
9.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26407011	45 mg 1 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PRIDOPIDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
7.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26407011	45 mg single, oral dose: 45 mg route of administration: Oral experiment type: SINGLE co-administered:	PRIDOPIDINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY106896	https://www.001chemical.com/chem/search?q=DY106896
1PlusChem LLC	1P00C9WU	https://www.1pchem.com/search?query=1P00C9WU
A2B Chem	AF71918	http://a2bchem.com/prod/AF71918
Angene	AGN-PC-0BMHVB	http://www.angenechemical.com/productshow/AGN-PC-0BMHVB.html
AstaTech	O11067	http://astatechinc.com/CPSResult.php?CRNO=O11067
Axon MedChem	1579	https://www.axonmedchem.com/product/1579
BOC Sciences	346688-38-8	http://www.bocsci.com/description.asp?cas=346688-38-8
Chem Scene	CS-0002733	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0002733
ChemShuttle	108423	https://www.chemshuttle.com/catalogsearch/result/?q=108423
Debye Scientific	DB-014417	https://www.debyesci.com/index.php?id=product&ext[cno]=DB-014417
Hairui	PRXM006	http://www.hairuichem.com/en/product/search.do?q=PRXM006
KeyOrganics	AS-50146	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-50146
Lab Network	LN01292490	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01292490
Matrix Scientific	132292	http://www.matrixscientific.com/132292.html
MedChem Express	HY-10684	https://www.medchemexpress.com/search.html?q=HY-10684&ft=&fa=&fp=
MolPort	MolPort-003-849-091	https://www.molport.com/shop/molecule-link/MolPort-003-849-091
Molcore	MC106896	http://www.molcore.com/CatMC106896.html
MuseChem	I008874	https://www.musechem.com/product/I008874.html
MuseChem	R006885	https://www.musechem.com/product/R006885.html
TargetMol	T7352	https://www.targetmol.com/search?keyword=T7352
Toronto Research Chemicals	I717200	https://www.trc-canada.com/product-detail/?CatNum=I717200
Toronto Research Chemicals	M326195	https://www.trc-canada.com/product-detail/?CatNum=M326195
eMolecules	17405693	https://orderbb.emolecules.com/search/#?query=17405693
eMolecules	93438902	https://orderbb.emolecules.com/search/#?query=93438902

PubMed

Title	Date	PubMed
The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat.	2006 Aug	16648369
Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).	2010 Mar 25	20155917

Patents

Sample Use Guides

In Vivo Use Guide

45 mg once or twice daily for 26 weeks

Route of Administration: Oral

In Vitro Use Guide

Administration of pridopidine (150 uM), the most effective dose, significantly reduced apoptosis in immortalized striatal knock-in cells expressing endogenous levels of mutant huntingtin and markedly enhanced phosphorylation state of prosurvival kinase ERK.

Name

Type

Language

PRIDOPIDINE HYDROCHLORIDE

Official Name

English

FR-310826

Code

English

ACR16 HYDROCHLORIDE

Code

English

4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride

Systematic Name

English

ACR-16 HYDROCHLORIDE

Code

English

ASP-2314 HCL

Code

English

PRIDOPIDINE HYDROCHLORIDE [USAN]

Common Name

English

PIPERIDINE, 4-(3-(METHYLSULFONYL)PHENYL)-1-PROPYL-, HYDROCHLORIDE (1:1)

Systematic Name

English

PRIDOPIDINE HYDROCHLORIDE [MI]

Common Name

English

ASP-2314 HYDROCHLORIDE

Code

English

FR310826

Code

English

Pridopidine hydrochloride [WHO-DD]

Common Name

English

ACR16 HCL

Code

English

ASP2314 HYDROCHLORIDE

Code

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/05/288